11 – 20 of 77
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
(
- Contribution to journal › Article
-
Mark
Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
(
- Contribution to journal › Article
-
Mark
Extracellular MRP8/14 is a regulator of β2 integrin-dependent neutrophil slow rolling and adhesion.
(
- Contribution to journal › Article
-
Mark
Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis.
(
- Contribution to journal › Article
-
Mark
S100A9 as a pharmacological target molecule in inflammation and cancer.
(
- Contribution to journal › Article
-
Mark
S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival.
(
- Contribution to journal › Article
-
Mark
Myeloid-related protein 14 promote inflammation and injury in meningitis.
(
- Contribution to journal › Article
- 2014
-
Mark
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
(
- Contribution to journal › Article
-
Mark
The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: Leukocyte- and context-specific effects.
(
- Contribution to journal › Article
-
Mark
High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome.
(
- Contribution to journal › Article